We are excited to announce that the Medical Affairs Summit Returns to Boston!

The Medical Affairs Summit is scheduled to take place on 12 – 13 October 2023 at the luxurious Encore Boston Harbor in Boston, MA, US. The event brings together key Clinical Trial Executives representing pharmaceutical industries in the Americas. The Summit offers a highly focused and interactive platform for attendees to address core concerns and find solutions tailored to their specific needs.

The Summit offers the opportunity for one-on-one business meetings, which allows sponsors to connect with key decision-makers in the industry. This can be instrumental in forging precious partnerships. This is an unparalleled opportunity for extensive networking among industry peers during one-on-one business meetings, event meals, cocktail receptions and leisure entertainment.

Previous attendees include:

  • Johnson & Johnson – Director, Global Program Leader – Oncology, Medical Affairs Operations
  • EMD Serono Inc.- Director, Strategic Planning and Performance Management
  • Janssen – Group Medical Director, Solid Tumors
  • Radius Health – Head: Medical Strategy & Integrated Evidence
  • Sobi Inc. – Director of Immunology, Medical Affairs
  • Vertex Pharmaceuticals – Medical Director

To enquire more information, please visit https://bit.ly/43CBrgl or directly contact Isidora Avraam at isidoraa@marcusevanscy.com.

#meMedAffairs

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.